Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients
Gut and Liver
;
: 255-262, 2018.
Artículo
en Inglés
| WPRIM
| ID: wpr-714616
ABSTRACT
BACKGROUND/AIMS:
Information regarding the efficacy of early infliximab treatment in pediatric patients with Crohn's disease (CD) is limited. We aimed to evaluate the impact of early combined immunosuppression on linear growth in pediatric patients with CD by performing step-up comparisons.METHODS:
This retrospective study included pediatric patients with moderate-to-severe CD, who received a combination therapy with infliximab and azathioprine for at least 3 years and sustained corticosteroid-free remission without loss of response. The z-scores of the growth indicators obtained at the time of diagnosis and annually for 3 years thereafter were compared between the two groups.RESULTS:
The early combined immunosuppression group displayed significantly increased linear growth 3 years after diagnosis (p=0.026). A significant difference was also observed in the linear growth 3 years after diagnosis between subgroups of Tanner stages 1–2 (p=0.016).CONCLUSIONS:
The early introduction of biologics should be considered to improve linear growth in pediatric patients with CD.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Azatioprina
/
Productos Biológicos
/
Enfermedad de Crohn
/
Estudios Retrospectivos
/
Terapia de Inmunosupresión
/
Diagnóstico
/
Infliximab
Tipo de estudio:
Estudio diagnóstico
/
Estudio observacional
Límite:
Humanos
Idioma:
Inglés
Revista:
Gut and Liver
Año:
2018
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS